kabutan

KYORIN Pharmaceutical Co.,Ltd.(4569) Summary

4569
TSE Prime
KYORIN Pharmaceutical Co.,Ltd.
1,623
JPY
-6
(-0.37%)
Mar 13, 3:30 pm JST
10.18
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
19.4
PBR
0.67
Yield
3.51%
Margin Trading Ratio
68.88
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
1,613 JPY 10.13 USD
Previous Close Mar 12
1,629 JPY 10.24 USD
High Mar 13, 10:14 am
1,640 JPY 10.30 USD
Low Mar 13, 9:00 am
1,613 JPY 10.13 USD
Volume
114,600
Trading Value
0.19B JPY 1.17M USD
VWAP
1623.75 JPY 10.19 USD
Minimum Trading Value
162,300 JPY 1,018 USD
Market Cap
0.10T JPY 0.61B USD
Number of Trades
303
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
347
1-Year High Apr 23, 2025
2,017
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 68,400 91,500 1.34
Feb 27, 2026 39,200 106,400 2.71
Feb 20, 2026 32,100 115,200 3.59
Feb 13, 2026 29,100 102,200 3.51
Feb 6, 2026 26,700 107,600 4.03
Company Profile
KYORIN Pharmaceutical Co., Ltd. is a mid-tier pharmaceutical company. Its main products include asthma medications and expectorants. The company also produces generic drugs and gastrointestinal medicines.
Sector
Pharmaceuticals
KYORIN Pharmaceutical Co., Ltd. primarily engages in the manufacture and sale of pharmaceuticals. The company focuses on prescription drugs such as asthma medications and expectorants, while also having a track record in generic drugs and COVID-19 detection reagents. With manufacturing and sales companies within its group, KYORIN has established an integrated business structure. The company procures some pharmaceutical raw materials from its affiliated companies. In recent years, KYORIN has undergone group restructuring, including the absorption and merger of wholly-owned subsidiaries, to improve management efficiency and accelerate decision-making processes. While adapting to changing medical needs, the company is also concentrating on developing new drugs using its proprietary drug discovery technologies.